Deutsche Bank Maintains Sell on AstraZeneca PLC (AZN) Feb 2026

Deutsche Bank on February 06, 2026 maintained a Sell rating on AstraZeneca PLC (AZN), while raising its price target to 11,500 GBp. The AZN analyst rating therefore signals continued caution from a major house even as the bank nudged fair value higher. This combination matters because it pairs a conservative recommendation with a slightly higher valuation, creating mixed signals for investors weighing near-term risk against longer-term potential.

Key AZN analyst rating update

Deutsche Bank on February 06, 2026 at 02:22 PM maintained a Sell rating on AstraZeneca PLC (AZN).

The same note raised the price target to 11,500 GBp from 11,000 GBp, per TheFly.

Analyst rationale behind the AZN analyst rating

Keeping a Sell while lifting a price target usually reflects mixed views on valuation and near-term catalysts.

Deutsche Bank’s action suggests measured confidence in longer term value, alongside caution on immediate growth or risk drivers.

AZN price target change and numeric implications

The new 11,500 GBp target is a 4.5% increase from 11,000 GBp and signals a modest upward revision in fair value.

AstraZeneca’s market cap stands near $599,029,554,833, which investors should weigh against the new price target.

Market reaction and AZN stock performance

The published note coincided with a -0.25% move in headline price change, a muted immediate market reaction.

AstraZeneca recently hit an all-time ADR high at $190.19, highlighting recent positive momentum despite the maintained Sell, per Investing.com.

Historical context on AstraZeneca analyst coverage

Deutsche Bank is a long-standing AstraZeneca watcher and its ratings carry weight among institutional investors.

Analyst coverage of AstraZeneca has been active amid regulatory milestones and M&A talk, which explains frequent price target updates and varied recommendations.

What the AZN analyst rating means for investors

A maintained Sell indicates analysts advise caution, but the higher target shows limited upside from Deutsche Bank’s view.

Investors should match this AZN analyst rating with company fundamentals, regulatory news, and personal risk tolerance before acting.

Final Thoughts

Deutsche Bank’s maintained Sell on AstraZeneca PLC (AZN) on February 06, 2026 combines caution with a modestly higher valuation. The bank raised its price target to 11,500 GBp, signaling a slightly improved fair value estimate while keeping a negative recommendation. For investors this means the near-term view remains cautious, but the updated target narrows downside expectations. The market reacted modestly, and recent company news, including an ADR record high and regulatory developments, adds context to the note. Meyka AI rates AZN with a grade of A. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Use this AZN analyst rating alongside your own analysis and risk profile. Meyka AI provides AI-powered market analysis tools to track such changes in real time.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.